Podcast: Rapamycin, genes and mouse lifespan research on slowing aging
In this podcast description, Dr. Rich Miller discusses mouse studies of genetic mutants, calorie restriction and drugs such as rapamycin, plus the difficulty of translating these results to humans. [1]
Automatic summary · not editorially reviewed
The key findings
The description says mouse studies used genetic mutants, calorie-restricted diets and drugs such as rapamycin, acarbose, canagliflozin and 17 alpha-estradiol to extend lifespan. [1]
The description reports that many anti-aging effects held up even when treatment started in middle age rather than early in life. [1]
The description says Dr. Miller works on aging rate indicators that could make human drug trials for aging more practical. [1]
The source at a glance
- Study type / format
- Podcast episode description summarizing animal and experimental aging research
- Population / context
- Mice in the described laboratory studies; the description does not specify human participants.
- Summary based on
- Creator description
- Original publication
- September 22, 2026
Mouse lifespan studies with mutants, diet and drugs
According to the description, Dr. Miller walks through decades of research in mice. The studies used genetic mutants, calorie-restricted diets and drugs including rapamycin, acarbose, canagliflozin and 17 alpha-estradiol to extend lifespan. The description says these interventions work through pathways such as mTOR and glucose regulation, and that some drugs affect males and females differently. It also reports the surprising finding that many of these effects hold up even when treatment starts in middle age rather than early in life. These are animal findings as described; the description does not present them as proven benefits for human lifespan.
Supporting source [1]
Why mouse results are hard to translate to humans
The description says the conversation covers the challenge of translating mouse research to humans. Dr. Miller is described as working on "aging rate indicators" that could make human drug trials for aging far more practical. The description does not report results from such human trials or name a validated indicator. It also says he calls for more dermatology involvement, including studying skin aging alongside the organs his lab has already examined.
Supporting source [1]
Supplement claims and the limits of this description
The episode closes, per the description, with a candid take on supplement industry claims and what current evidence actually supports for slowing aging today. The description does not specify which supplements or claims were discussed, so no product or dose can be drawn from it. It labels the content as educational and informational, reflecting the speakers' personal research findings and opinions, not medical advice, and notes that the discussion involves animal studies and experimental research. Only this description was available: the video and transcript were not reviewed.
Supporting source [1]
How to interpret this
Only the video description was available; the video and transcript were not reviewed. The description gives no sample sizes, follow-up times or effect sizes, and the findings described come from animal and experimental research.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
The Science of Skin Podcast · youtube.com · September 22, 2026